The Role of Non-statin Therapy to Improve Cardiovascular Outcomes

Abstract

All major studies generated evidence that validated the association between hyperlipidemia and cardiovascular disease. Low-Density Lipoprotein (LDL) has always been the target for risk reduction and the most frequently used therapeutic option. Statins reduce the LDL and improves the cardiovascular (CV) outcomes. However, in specific clinical cases where statins cannot be used, the therapy must include non-statin drugs. There are many options available, but the not all improve the CV outcome. Ezetimibe and PCSK9 inhibitors had clear evidence of benefit to reduce atherosclerotic cardiovascular disease risk, while other therapy are showing less evidence. The current review highlights the evidence related to non-statins in the reduction of CV outcomes.